Stratified analyses
. | Death . | Relapse . | Death or relapse* . | |||
---|---|---|---|---|---|---|
HR (95% CI) . | P† . | HR (95% CI) . | P† . | HR (95% CI) . | P† . | |
IPSS Intermediate-1 | ||||||
Normal/mild/moderate‡ | 1 | NA | 1 | NA | 1 | NA |
Severe | 1.3 (0.6-2.6) | .5 | 3.8 (1.2-12.0) | .02 | 1.6 (0.8-3.0) | .19 |
IPSS Intermediate-2/high | ||||||
Normal/mild/moderate‡ | 1 | NA | 1 | NA | 1 | NA |
Severe | 1.7 (0.9-3.5) | .12 | 2.3 (0.9-6.2) | .08 | 2.0 (1.0-3.8) | .04 |
Marrow myeloblast percentage < 5% | ||||||
Normal myeloblasts‡ | 1 | NA | 1 | NA | 1 | NA |
Abnormal myeloblasts | 1.2 (0.6-2.3) | .63 | 3.7 (1.2-11.3) | .02 | 1.4 (0.7-2.5) | .34 |
. | Death . | Relapse . | Death or relapse* . | |||
---|---|---|---|---|---|---|
HR (95% CI) . | P† . | HR (95% CI) . | P† . | HR (95% CI) . | P† . | |
IPSS Intermediate-1 | ||||||
Normal/mild/moderate‡ | 1 | NA | 1 | NA | 1 | NA |
Severe | 1.3 (0.6-2.6) | .5 | 3.8 (1.2-12.0) | .02 | 1.6 (0.8-3.0) | .19 |
IPSS Intermediate-2/high | ||||||
Normal/mild/moderate‡ | 1 | NA | 1 | NA | 1 | NA |
Severe | 1.7 (0.9-3.5) | .12 | 2.3 (0.9-6.2) | .08 | 2.0 (1.0-3.8) | .04 |
Marrow myeloblast percentage < 5% | ||||||
Normal myeloblasts‡ | 1 | NA | 1 | NA | 1 | NA |
Abnormal myeloblasts | 1.2 (0.6-2.3) | .63 | 3.7 (1.2-11.3) | .02 | 1.4 (0.7-2.5) | .34 |